Form 4: Boundless Bio Director Nancy Whiting Granted 16,000 Stock Options

Boundless Bio, Inc. Director Nancy Whiting was granted 16,000 stock options with an exercise price of $1.03, vesting over 12 months.

Summary

• Nancy Whiting, a Director of Boundless Bio, Inc. (BOLD), was granted 16,000 stock options.
• The transaction date for this grant was June 23, 2025.
• The exercise price for these stock options is $1.03 per share.
• The options will vest in substantially equal monthly installments over the 12 months following June 23, 2025.
• Any remaining unvested portion will vest on the date of the next annual meeting of stockholders if it occurs prior to June 23, 2026.
• Vesting is contingent upon Ms. Whiting's continued service on the issuer's board of directors.
• The expiration date for these stock options is June 22, 2035.

Sentiment

Score: 6

Explanation: The sentiment is mildly positive as it indicates standard corporate governance and incentive alignment, with no negative financial implications beyond routine dilution.

Positives

• The grant of stock options aligns the interests of Director Nancy Whiting with those of the shareholders, incentivizing long-term performance and value creation.
• The vesting schedule over 12 months encourages continued service and commitment from the director.

Negatives

• The issuance of new stock options, upon exercise, could lead to minor dilution for existing shareholders, although this is a standard component of executive and director compensation.

Risks

• The vesting of the stock options is subject to the reporting person's continuing service on the issuer's board of directors, meaning unvested options could be forfeited if service ceases.

Future Outlook

The stock options granted to Director Nancy Whiting are set to vest in substantially equal monthly installments over the 12 months following June 23, 2025, or potentially earlier upon the next annual meeting of stockholders if it occurs before June 23, 2026, contingent on her continued service.

Industry Context

The grant of stock options to a director is a common practice in the biotechnology and pharmaceutical industries, particularly for companies like Boundless Bio, Inc. (BOLD), which are often in growth phases. This compensation structure is designed to attract and retain experienced board members and align their financial interests with the long-term success of the company, which is crucial in a capital-intensive and research-driven sector.

Comparison to Industry Standards

• Director compensation packages in the biotech sector frequently include equity components like stock options or restricted stock units, reflecting a standard approach to incentivize performance and align interests.
• The vesting schedule of 12 months is relatively short for director options, which sometimes vest over multiple years or upon specific milestones, but it is not uncommon for new grants or annual refreshers.
• The exercise price being set at the market price on the grant date ($1.03) is standard for incentive stock options, ensuring that the director benefits only if the company's stock price appreciates.

Related Party Transactions

• The grant of stock options to Nancy Whiting, a Director of Boundless Bio, Inc., constitutes a related party transaction as it involves compensation to a member of the company's board of directors.

Stakeholder Impact

• Shareholders: Potential for minor dilution upon exercise of options, but also benefit from increased alignment of director's interests with long-term stock performance.
• Employees: No direct impact mentioned, but generally, such grants are part of a broader compensation philosophy that can affect morale and retention.
• Management: Reinforces the company's compensation structure for its leadership.

Next Steps

• The stock options will begin vesting in monthly installments starting June 23, 2025.
• The company will continue to monitor and report on the beneficial ownership of its directors and officers as required by SEC regulations.

Key Dates

Keywords

Boundless Bio, BOLD, Stock Option Grant, SEC Form 4, Insider Transaction, Director Compensation, Equity Incentive, Nancy Whiting